NASDAQ:PTIE - Pain Therapeutics Stock Price, Price Target & More

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

Pain Therapeutics's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

Pain Therapeutics, Inc. (NASDAQ:PTIE) issued its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.33. View Pain Therapeutics' Earnings History.

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Pain Therapeutics.

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pain Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Some companies that are related to Pain Therapeutics include Celsion (CLSN), Zosano Pharma (ZSAN), Addex Pharmaceuticals (ADDXF), IntelGenx Technologies (IGXT), Imprimis Pharmaceuticals (IMMY), vTv Therapeutics (VTVT), Heat Biologics (HTBX), Moleculin Biotech (MBRX), AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Acerus Pharmaceuticals (TRLPF), Evoke Pharma (EVOK), Capricor Therapeutics (CAPR), Onconova Therapeutics (ONTX) and Chiasma (CHMA).

News articles about PTIE stock have trended somewhat positive on Friday, Accern Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pain Therapeutics earned a daily sentiment score of 0.08 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.52 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTIE stock can currently be purchased for approximately $2.22.

Pain Therapeutics has a market capitalization of $14.96 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.

Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.